Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This study tests a combination of two experimental drugs, TQB2930 and TQB2102, both designed to attack cancer cells that have a protein called HER2. The trial enrolls about 178 adults with advanced solid tumors that express HER2 and have not responded to standard treatments. The …

This phase 3 trial is testing a new drug called TQB2930, given with chemotherapy, for people with HER2-positive advanced breast cancer who have already tried at least two prior anti-HER2 treatments. The study compares TQB2930 plus chemo to the standard drug trastuzumab plus chemo…

This study tests an experimental drug called TQH3906 in adults with moderate-to-severe ulcerative colitis or Crohn's disease. About 135 participants will receive either the drug or a placebo for 12 weeks to see if it safely reduces inflammation and improves symptoms. The goal is …

This study tests an experimental drug called TQB2102 in people with advanced bile duct cancer that has a specific marker (HER2-positive). The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 102 adults aged 18 to 75 with good organ function are bein…

This phase 3 trial compares a new drug called TQB2102 against a standard chemotherapy combination (TCbHP) for people with HER2-positive breast cancer. The goal is to see if TQB2102 works better at eliminating cancer before surgery. About 544 participants will be randomly assigned…

This Phase 1 trial tests TQB6411, an antibody-drug conjugate designed to bind to EGFR and c-Met proteins on tumor cells, blocking their growth signals and releasing a toxin to kill the cells. The study will enroll 216 adults with advanced malignant tumors to find the safest dose …

This study tests a new drug called LM-108, which clears certain immune cells from tumors, combined with standard chemotherapy and another immunotherapy. The goal is to see if this mix is safe and can slow or shrink advanced solid tumors. About 194 adults with advanced cancers wil…

This early-stage trial is testing a new drug called TQB2934 in 42 people with multiple myeloma, a type of blood cancer. TQB2934 is a bispecific antibody designed to help the body's T cells recognize and kill cancer cells. The main goals are to check the drug's safety and how it m…

This phase 2 trial is testing TQB2102, a drug that combines an antibody with chemotherapy to specifically attack lung cancer cells that have HER2 gene abnormalities. The study will enroll 270 adults with advanced non-small cell lung cancer that cannot be surgically removed. Resea…

This Phase 2 trial is testing whether adding an experimental immunotherapy (TQB2868) and a targeted drug (anlotinib) to standard chemotherapy can help people with pancreatic cancer that has spread. The study will enroll 80 adults who have not had prior treatment. Researchers will…